{"product_id":"retatrutide-10mg","title":"RETATRUTIDE 10MG","description":"\u003cp\u003eRetatrutide is one of the most promising new weight-loss and metabolic health drugs currently in clinical development. Unlike existing GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) or dual agonists like tirzepatide (Mounjaro, Zepbound), Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. This unique mechanism has shown unprecedented results in early clinical trials, with participants losing over 24% of their body weight in less than a year at the highest studied doses.\u003c\/p\u003e\n\u003cp\u003eRetatrutide (also known as LY-3437943) is an experimental medication developed by Eli Lilly that is being studied as a next-generation treatment for obesity, overweight, and related metabolic conditions such as type 2 diabetes. It represents a new class of therapies called “triple agonists,” meaning it simultaneously activates three key hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This combined activity helps regulate appetite, improve insulin sensitivity, slow gastric emptying to promote fullness, and enhance fat burning.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey Points:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRetatrutide is given as a once-weekly subcutaneous injection.\u003c\/li\u003e\n\u003cli\u003eStepwise escalation is critical to reduce gastrointestinal intolerance.\u003c\/li\u003e\n\u003cli\u003eMost participants in trials reached 8–12 mg weekly, which delivered the strongest results\u003c\/li\u003e\n\u003cli\u003eDosing protocols may be refined in Phase 3 and post-approval, but gradual titration will remain the standard.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eReconstitute:\u003c\/strong\u003e Add 2mL bacteriostatic water (40 units = 2mg)\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTypical weekly range:\u003c\/strong\u003e 2-8 mg once weekly (gradual escalation over 8–12 weeks).\u003c\/p\u003e\n\u003cp\u003eWeeks 1-4 : 2mg = 40 units\u003cbr\u003eWeeks 5-8 : 4mg = 80 units\u003cbr\u003eWeeks 9-12 :  6mg = 120 units\u003cbr\u003eWeeks 13+ : 8mg = 160 units\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCommon Side Effects :\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAcross Phase 2 trials, participants experienced dose-dependent GI symptoms that are characteristic of GLP-1 receptor agonists:\u003c\/p\u003e\n\u003cp\u003eNausea (most frequent, especially during dose escalation)\u003cbr\u003eVomiting (typically mild to moderate, subsiding with continued use)\u003cbr\u003eDiarrhea and constipation (fluctuating depending on individual tolerance)\u003cbr\u003eAbdominal discomfort (transient and often improved over time)\u003c\/p\u003e","brand":"nexus pharmaceuticals","offers":[{"title":"Default Title","offer_id":48830386471166,"sku":null,"price":3500.0,"currency_code":"THB","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0828\/0604\/6974\/files\/retabox-Photoroom.jpg?v=1788189355","url":"https:\/\/pepthai.com\/products\/retatrutide-10mg","provider":"PEPTHAI","version":"1.0","type":"link"}